Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:002294)

Market Cap	35.08B -18.4%
Revenue (ttm)	4.52B +13.4%
Net Income	676.45M +12.4%
EPS	0.60 +11.2%
Shares Out	1.11B
PE Ratio	52.41
Forward PE	44.32
Dividend	0.55 (1.76%)
Ex-Dividend Date	May 26, 2026

Volume	14,352,506
Open	32.43
Previous Close	31.22
Day's Range	30.66 - 32.43
52-Week Range	30.82 - 70.99
Beta	-0.16
Analysts	Strong Buy
Price Target	60.00 (+90.66%)
Earnings Date	Aug 21, 2026

About SHE:002294

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of pharmaceuticals and medical devices in China. The company is involved in the production and supply of pharmaceutical products in the fields of chronic diseases, including cardiovascular and cerebrovascular diseases, diabetes, oncology, osteoporosis, anti-infective diseases, and chronic kidney diseases. It also engages in the research and development, production, and sale of high-end interventional medical devices, such as cardiovascular and...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 4,087
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002294

Financial Performance

In 2025, SHE:002294's revenue was 4.35 billion, an increase of 8.48% compared to the previous year's 4.01 billion. Earnings were 651.50 million, an increase of 8.30%.